Zymeworks Appoints Oleg Nodelman to Board of Directors
Biotech investor and EcoR1 Capital Founder, Oleg Nodelman, joins Zymeworks' Board of Directors to support long-term strategy and growth.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
Zymeworks Inc. has announced the appointment of Oleg Nodelman to its Board of Directors, effective February 17, 2025. As the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment firm, Mr. Nodelman brings over two decades of experience in investment management, business development, and biotech strategy. His addition marks the seventh new board appointment in Zymeworks' ongoing board renewal process.
“As the largest current stockholder of Zymeworks, we at EcoR1 are aligned with the company’s mission and long-term vision,” said Mr. Nodelman. Zymeworks CEO Kenneth Galbraith highlighted his extensive industry expertise as a key asset in advancing the company’s pipeline of novel biotherapeutics.
With a strong track record in biotech investments and current board roles at Galapagos NV and AnaptysBio, Mr. Nodelman’s appointment strengthens Zymeworks' commitment to delivering transformative therapies and driving lasting value for patients and stockholders.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion